GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (XTAE:EVGN) » Definitions » Shiller PE Ratio

Evogene (XTAE:EVGN) Shiller PE Ratio : (As of May. 01, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Evogene Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Evogene Shiller PE Ratio Historical Data

The historical data trend for Evogene's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evogene Shiller PE Ratio Chart

Evogene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 13.13 - -

Evogene Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evogene's Shiller PE Ratio

For the Biotechnology subindustry, Evogene's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evogene's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evogene's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Evogene's Shiller PE Ratio falls into.



Evogene Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Evogene's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Evogene's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.485/129.4194*129.4194
=-0.485

Current CPI (Dec. 2023) = 129.4194.

Evogene Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.351 99.695 -0.456
201406 -0.485 100.560 -0.624
201409 -0.635 100.428 -0.818
201412 -0.709 99.070 -0.926
201503 -0.485 99.621 -0.630
201506 -0.747 100.684 -0.960
201509 -0.485 100.392 -0.625
201512 -0.822 99.792 -1.066
201603 -0.485 100.470 -0.625
201606 -0.672 101.688 -0.855
201609 -0.747 101.861 -0.949
201612 -0.971 101.863 -1.234
201703 -0.709 102.862 -0.892
201706 -0.672 103.349 -0.842
201709 -0.747 104.136 -0.928
201712 -0.896 104.011 -1.115
201803 -0.784 105.290 -0.964
201806 -0.709 106.317 -0.863
201809 -0.709 106.507 -0.862
201812 -0.859 105.998 -1.049
201903 -0.560 107.251 -0.676
201906 -0.597 108.070 -0.715
201909 -0.597 108.329 -0.713
201912 -0.896 108.420 -1.070
202003 -0.896 108.902 -1.065
202006 -0.597 108.767 -0.710
202009 -0.635 109.815 -0.748
202012 -0.934 109.897 -1.100
202103 -0.635 111.754 -0.735
202106 -0.560 114.631 -0.632
202109 -0.709 115.734 -0.793
202112 -0.672 117.630 -0.739
202203 -0.747 121.301 -0.797
202206 -0.784 125.017 -0.812
202209 -0.597 125.227 -0.617
202212 -0.261 125.222 -0.270
202303 -0.560 127.348 -0.569
202306 -0.635 128.729 -0.638
202309 -0.299 129.860 -0.298
202312 -0.485 129.419 -0.485

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evogene  (XTAE:EVGN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Evogene Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Evogene's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evogene (XTAE:EVGN) Business Description

Traded in Other Exchanges
Address
13 Gad Feinstein Street, Park Rehovot, P.O. Box 4173, Ness Ziona, Rehovot, ISR, 7414002
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.